These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 738426)

  • 21. Effects of muramyl dipeptide treatment on resistance to infection with Toxoplasma gondii in mice.
    Krahenbuhl JL; Sharma SD; Ferraresi RW; Remington JS
    Infect Immun; 1981 Feb; 31(2):716-22. PubMed ID: 7216470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of treatment with muramyl dipeptide and certain of its analogs on resistance to Listeria monocytogenes in mice.
    Humphres RC; Henika PR; Ferraresi RW; Krahenbuhl JL
    Infect Immun; 1980 Nov; 30(2):462-6. PubMed ID: 7439991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant activity of some nonpyrogenic hydrophobic analogues of muramyl dipeptide in enhancing the primary humoral and cell mediated immune responses in guinea pig model.
    Saxena RP; Puri A; Saxena KC; Shukla R; Haq W; Rizvi SY; Kundu B; Mathur KB
    Indian J Exp Biol; 1991 Feb; 29(2):111-5. PubMed ID: 1869292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regression of line-10 hepatocarcinoma with synthetic quinonyl muramyl dipeptide in strain-2 guinea pigs.
    Tanio Y; Souma H; Tokushima Y; Yamamura Y; Azuma I
    Gan; 1983 Apr; 74(2):192-5. PubMed ID: 6862142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brucella abortus vaccines: comparison of protection provided by immunopotentiated 45/20 bacterins and live strain 19 vaccine in guinea pigs.
    Woodard LF; Toone NM; Jasman RL
    Am J Vet Res; 1981 Nov; 42(11):1959-62. PubMed ID: 6802042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse.
    Parant M; Parant F; Chedid L; Yapo A; Petit JF; Lederer E
    Int J Immunopharmacol; 1979; 1(1):35-41. PubMed ID: 551094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Past, present and future of the synthetic immunoadjuvant MDP and its analogs.
    Chedid L; Lederer E
    Biochem Pharmacol; 1978; 27(18):2183-6. PubMed ID: 365182
    [No Abstract]   [Full Text] [Related]  

  • 28. Protective effect of muramyl dipeptide analogs against infections of Pseudomonas aeruginosa or Candida albicans in mice.
    Fraser-Smith EB; Matthews TR
    Infect Immun; 1981 Dec; 34(3):676-83. PubMed ID: 7333666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity.
    Chedid LA; Parant MA; Audibert FM; Riveau GJ; Parant FJ; Lederer E; Choay JP; Lefrancier PL
    Infect Immun; 1982 Feb; 35(2):417-24. PubMed ID: 7035362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human alveolar macrophages: potentiation of their tumoricidal activity by liposome-encapsulated muramyl dipeptide.
    Sone S; Tsubura E
    J Immunol; 1982 Sep; 129(3):1313-7. PubMed ID: 7108208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epithelioid granuloma formation by a synthetic bacterial cell wall component, muramyl dipeptide (MDP).
    Tanaka A; Emori K
    Am J Pathol; 1980 Mar; 98(3):733-48. PubMed ID: 6767407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunoadjuvant activities of synthetic N-acetyl-muramyl-peptides or -amino acids.
    Kotani S; Watanabe Y; Kinoshita F; Shimono T; Morisaki I
    Biken J; 1975 Jun; 18(2):105-11. PubMed ID: 1180867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Fundamental studies to use the adjuvant activity of 6-o-acylmuramyldipeptides to potentiate cell and humoral immune responses for practical purposes].
    Tsujimoto M
    J Osaka Univ Dent Sch; 1981 Jun; 26(1):63-83. PubMed ID: 6945426
    [No Abstract]   [Full Text] [Related]  

  • 34. Influence of a synthetic adjuvant (MDP) on qualitative and quantitative changes of serum globulins.
    Leclerc C; Audibert F; Chedid L
    Immunology; 1978 Dec; 35(6):963-70. PubMed ID: 738768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis of carbohydrate analogs (positional, configurational, and optical) of n-acetylmuramoyl-L-alanyl-D-isoglutamine, and their immunoadjuvant activities.
    Hasegawa A; Kaneda Y; Goh Y; Nishibori K; Kiso M; Azuma I
    Carbohydr Res; 1981 Aug; 94(2):143-63. PubMed ID: 7273036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs.
    Phillips NC; Chedid L; Bernard JM; Level M; Lefrancier P
    J Biol Response Mod; 1987 Dec; 6(6):678-91. PubMed ID: 3450784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Adjuvant activity and adjuvant arthritis].
    Tanaka A
    Kekkaku; 1980 Oct; 55(10):465-7. PubMed ID: 7230587
    [No Abstract]   [Full Text] [Related]  

  • 38. Kinetics of the humoral and cellular immune response of guinea pigs after injection of the synthetic adjuvant N-acetylmuramyl L-alanyl-D-isoglutamine: comparison with Freund complete adjuvant.
    Souvannavong V; Adam A; Lederer E
    Infect Immun; 1978 Mar; 19(3):966-71. PubMed ID: 346491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Muramyl dipeptide stimulation of particle clearance in several animal species.
    Waters RV; Ferraresi RW
    J Reticuloendothel Soc; 1980 Nov; 28(5):457-71. PubMed ID: 7441647
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunotherapy of experimental cancer with a mixture of synthetic muramyl dipeptide and trehalose dimycolate.
    Yarkoni E; Lederer E; Rapp HJ
    Infect Immun; 1981 Apr; 32(1):273-6. PubMed ID: 7216489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.